Grape King Bio Ltd (1707.TW)
TWD 151.0
(0.0%)
TWD 151.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.03 Billion TWD | -2.03% |
| 2022 | 5.92 Billion TWD | 6.95% |
| 2021 | 5.54 Billion TWD | 5.96% |
| 2020 | 5.23 Billion TWD | 0.02% |
| 2019 | 5.23 Billion TWD | 5.05% |
| 2018 | 4.97 Billion TWD | -11.25% |
| 2017 | 5.61 Billion TWD | -1.31% |
| 2016 | 5.68 Billion TWD | 24.32% |
| 2015 | 4.57 Billion TWD | 15.43% |
| 2014 | 3.96 Billion TWD | 8.44% |
| 2013 | 3.65 Billion TWD | 19.31% |
| 2012 | 3.06 Billion TWD | 23.14% |
| 2011 | 2.48 Billion TWD | 18.0% |
| 2010 | 2.1 Billion TWD | 16.56% |
| 2009 | 1.8 Billion TWD | 295.73% |
| 2008 | 456.82 Million TWD | 26.39% |
| 2007 | 361.44 Million TWD | 8.6% |
| 2006 | 332.82 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.55 Billion TWD | 23.04% |
| 2024 Q1 | 1.26 Billion TWD | -24.51% |
| 2023 Q2 | 1.62 Billion TWD | 24.93% |
| 2023 Q1 | 1.3 Billion TWD | -25.47% |
| 2023 Q4 | 1.67 Billion TWD | 21.48% |
| 2023 Q3 | 1.37 Billion TWD | -15.52% |
| 2023 FY | 5.8 Billion TWD | -2.03% |
| 2022 Q3 | 1.35 Billion TWD | -16.43% |
| 2022 FY | 5.92 Billion TWD | 6.95% |
| 2022 Q2 | 1.61 Billion TWD | 33.32% |
| 2022 Q1 | 1.21 Billion TWD | -24.4% |
| 2022 Q4 | 1.74 Billion TWD | 29.42% |
| 2021 Q3 | 1.35 Billion TWD | -4.28% |
| 2021 FY | 5.54 Billion TWD | 5.96% |
| 2021 Q1 | 1.16 Billion TWD | -22.1% |
| 2021 Q2 | 1.41 Billion TWD | 21.27% |
| 2021 Q4 | 1.6 Billion TWD | 18.33% |
| 2020 Q1 | 1.2 Billion TWD | -18.17% |
| 2020 Q3 | 1.21 Billion TWD | -7.25% |
| 2020 Q4 | 1.49 Billion TWD | 23.37% |
| 2020 Q2 | 1.31 Billion TWD | 8.47% |
| 2020 FY | 5.23 Billion TWD | 0.02% |
| 2019 FY | 5.23 Billion TWD | 5.05% |
| 2019 Q3 | 1.2 Billion TWD | -13.44% |
| 2019 Q2 | 1.38 Billion TWD | 18.91% |
| 2019 Q1 | 1.16 Billion TWD | -15.61% |
| 2019 Q4 | 1.47 Billion TWD | 22.9% |
| 2018 Q1 | 1.08 Billion TWD | -29.9% |
| 2018 Q4 | 1.38 Billion TWD | 18.92% |
| 2018 Q3 | 1.16 Billion TWD | -14.12% |
| 2018 FY | 4.97 Billion TWD | -11.25% |
| 2018 Q2 | 1.35 Billion TWD | 25.29% |
| 2017 Q3 | 1.3 Billion TWD | -11.97% |
| 2017 Q1 | 1.29 Billion TWD | -13.07% |
| 2017 Q2 | 1.47 Billion TWD | 14.28% |
| 2017 Q4 | 1.54 Billion TWD | 18.56% |
| 2017 FY | 5.61 Billion TWD | -1.31% |
| 2016 Q1 | 1.29 Billion TWD | 3.38% |
| 2016 FY | 5.68 Billion TWD | 24.32% |
| 2016 Q4 | 1.48 Billion TWD | 8.52% |
| 2016 Q3 | 1.36 Billion TWD | -10.78% |
| 2016 Q2 | 1.53 Billion TWD | 18.69% |
| 2015 Q2 | 1.2 Billion TWD | 13.82% |
| 2015 Q1 | 1.05 Billion TWD | -2.86% |
| 2015 FY | 4.57 Billion TWD | 15.43% |
| 2015 Q4 | 1.25 Billion TWD | 18.51% |
| 2015 Q3 | 1.05 Billion TWD | -12.46% |
| 2014 Q3 | 932.1 Million TWD | -10.95% |
| 2014 Q2 | 1.04 Billion TWD | 17.36% |
| 2014 Q1 | 891.83 Million TWD | -2.95% |
| 2014 FY | 3.96 Billion TWD | 8.44% |
| 2014 Q4 | 1.09 Billion TWD | 17.03% |
| 2013 Q4 | 918.91 Million TWD | 4.45% |
| 2013 Q2 | 1.03 Billion TWD | 25.15% |
| 2013 FY | 3.65 Billion TWD | 19.31% |
| 2013 Q1 | 823.7 Million TWD | -7.06% |
| 2013 Q3 | 879.77 Million TWD | -14.66% |
| 2012 Q3 | 747.98 Million TWD | -5.09% |
| 2012 Q2 | 788.1 Million TWD | 21.84% |
| 2012 Q1 | 646.86 Million TWD | 0.93% |
| 2012 FY | 3.06 Billion TWD | 23.14% |
| 2012 Q4 | 886.3 Million TWD | 18.49% |
| 2011 Q2 | 615.79 Million TWD | 12.3% |
| 2011 Q1 | 548.36 Million TWD | -5.91% |
| 2011 Q4 | 640.92 Million TWD | -5.94% |
| 2011 FY | 2.48 Billion TWD | 18.0% |
| 2011 Q3 | 681.43 Million TWD | 10.66% |
| 2010 Q4 | 582.79 Million TWD | -0.89% |
| 2010 FY | 2.1 Billion TWD | 16.56% |
| 2010 Q3 | 588.03 Million TWD | 10.91% |
| 2010 Q2 | 530.18 Million TWD | 30.53% |
| 2010 Q1 | 406.17 Million TWD | 0.0% |
| 2009 FY | 1.8 Billion TWD | 295.73% |
| 2008 FY | 456.82 Million TWD | 26.39% |
| 2007 FY | 361.44 Million TWD | 8.6% |
| 2006 FY | 332.82 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Standard Chem & Pharm CO., LTD. | 1.46 Billion TWD | -312.01% |
| Maywufa Company Ltd. | 854.37 Million TWD | -606.876% |
| ScinoPharm Taiwan, Ltd. | 901.49 Million TWD | -569.924% |
| Lotus Pharmaceutical Co., Ltd. | 4.48 Billion TWD | -34.781% |
| LIWANLI Innovation Co., Ltd. | 54.86 Million TWD | -10907.453% |
| YungShin Global Holding Corporation | 2.04 Billion TWD | -194.933% |
| PhytoHealth Corporation | 67.64 Million TWD | -8828.269% |
| SCI Pharmtech, Inc. | 190.02 Million TWD | -3078.22% |
| Formosa Laboratories, Inc. | 1.24 Billion TWD | -383.785% |
| PharmaEssentia Corporation | 4.49 Billion TWD | -34.355% |
| Bora Pharmaceuticals Co., LTD. | 1.74 Billion TWD | -246.671% |